A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children
A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children
Sponsor: Guangxi Center for Disease Control and Prevention
Listed as NCT01569581, this PHASE3 trial focuses on The Efficacy of Inactivated EV71 Vaccine (KMB17) Against HFMD in Chinese Children and Infants and remains completed. Sponsored by Guangxi Center for Disease Control and Prevention, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Completed PHASE3
-
Dec 2022 — Oct 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangxi Center for Disease Control and Prevention
- Institute of Medical Biology, Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .